Verastem improves progression-free survival in Phase III trial for CLL and SLL
US-based biopharmaceutical firm Verastem has reported positive top-line results from the Phase III DUO clinical trial of duvelisib to treat relapsed or refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Leukemia | Lymphoma | Pharmaceuticals